Movement Disorders-Original Article

Journal of Neural Transmission

, Volume 117, Issue 6, pp 759-763

Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox® or Dysport®

  • Katja KolleweAffiliated withMovement Disorders Section, Department of Neurology, Hannover Medical School Email author 
  • , Bahram MohammadiAffiliated withMovement Disorders Section, Department of Neurology, Hannover Medical School
  • , Reinhard DenglerAffiliated withMovement Disorders Section, Department of Neurology, Hannover Medical School
  • , Dirk DresslerAffiliated withMovement Disorders Section, Department of Neurology, Hannover Medical School

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Botulinum toxin is considered the treatment of choice for hemifacial spasm (HFS) and reinnervation synkinesias (RS). We present 133 patients with HFS (n = 97) and RS (n = 36) who have been treated with either Botox® (n = 78) or Dysport® (n = 55) exclusively for 6 years (range 2–12 years). The Botox® dose was 21 ± 8 MU, the Dysport® dose 46 ± 22 MU. The therapeutic effect started after 7.1 ± 2.3 days and lasted for 12.5 ± 3.9 weeks. It was stable throughout the observation period in 85% of all patients. Adverse effects occurred in 5.4% of injection series. No patient terminated treatment because of unsatisfactory results. Secondary therapy failure did not occur. With an effective conversion ratio of Botox®:Dysport® = 1:2.56 there were no differences between both drugs with respect to therapeutic efficacy and adverse effects thus confirming the hypothesis that there may not be intrinsic differences between both products.

Keywords

Hemifacial spasm Reinnervation sykinesias Botulinum toxin Conversion factor Botox® Dysport®